Explore Our Biomarker Menu

Biological or Clinical Significance:

HumanMN/CA9gene is a novel member of the carbonic anhydrase (CA) family, which codes for widely distributed catalysts of the reversible conversion of carbon dioxide to carbonic acid. So far, MN/CA IX is the only tumor-associated CA isoenzyme. The entire genomic sequence ofMN/CA9,including the 5′-flanking region, encompasses 10.9 kb. The coding sequence is divided into 11 exons, whose organization and relationships to predicted protein domains suggest that the gene arose by exon shuffling.

Exon 1 encodes a signal peptide and a proteoglycan-related region. Exons 2–8 code for a CA domain with a highly conserved active site. The exon/intron pattern of the CA coding region is similar but not identical to other described animal kingdom α-CA genes. Exons 10 and 11 encode a transmembrane anchor and an intracytoplasmic tail, respectively. 

Sequence of the proximate 5′ end of the flanking region shows extensive homology to the long terminal repeats of HERV-K endogenous retroviruses. The putativeMN/CA9promoter immediately preceding the transcription start site does not possess a TATA box, but contains consensus sequences for the AP1, AP2, p53, and Inr transcription factors. This study will allow further investigations of the molecular events regulating expression of MN/CA IX as well as elucidation of its biological function.

References:

Analyte:

CA9

Matrix:

Human Serum

Status:

Experienced Running

Sensitivity-LLOQ:

4.47 pg/mL

Sensitivity-ULOQ:

platform

Ella

Required Sample Volume

Disease State:

MSD Panel:

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.


    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.